Glaucoma Global Market Report 2025

Glaucoma refers to a group of eye conditions that damage the optic nerve, typically due to increased intraocular pressure (IOP). If left untreated, this damage can lead to progressive and irreversible vision loss, making glaucoma one of the leading causes of blindness worldwide. Early detection through regular eye exams is essential to prevent vision impairment.

The primary types of glaucoma are open-angle glaucoma, angle-closure glaucoma, and others. Open-angle glaucoma occurs when the eye's drainage angle remains open, but the trabecular meshwork becomes progressively blocked, resulting in elevated IOP. It can be diagnosed using various methods such as tonometry, ophthalmoscopy, perimetry, and gonioscopy. Treatment includes several drug classes, including beta-blockers, prostaglandins, alpha-adrenergic agonists, carbonic anhydrase inhibitors, and combination drugs. These treatments are administered through oral medications, injections, intravitreal injections, and other routes, with end users such as hospitals, ophthalmic clinics, and ambulatory surgical centers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The glaucoma market research report is one of a series of new reports from The Business Research Company that provides glaucoma market statistics, including glaucoma industry global market size, regional shares, competitors with a glaucoma market share, detailed glaucoma market segments, market trends and opportunities, and any further data you may need to thrive in the glaucoma industry. This glaucoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The glaucoma market size has grown strongly in recent years. It will grow from $7.76 billion in 2024 to $8.2 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to increasing awareness of eye health, increasing healthcare spending, growing adoption of telemedicine for eye care, expanding healthcare infrastructure, increase in government healthcare initiatives.

The glaucoma market size is expected to see strong growth in the next few years. It will grow to $10.12 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to aging population, rising prevalence of glaucoma, growing demand for minimally invasive surgeries, rising prevalence of diabetes, rising prevalence of hypertension. Major trends in the forecast period include advancements in diagnostic technologies, availability of new drug treatments, technological innovations in surgical devices, availability of combination therapies, adoption of robotic surgeries.

The forecast of 5.4% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for the U.S. by restricting access to minimally invasive glaucoma drainage devices and prostaglandin analogs imported from Israel and France, potentially compromising vision preservation and increasing ophthalmology treatment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of chronic eye conditions is expected to drive growth in the glaucoma market. Chronic eye conditions are long-lasting disorders that impact the eyes, often causing ongoing vision impairment or discomfort, necessitating continuous management or treatment. Factors contributing to the rise of these conditions include an aging population, more screen time, lifestyle changes, and higher rates of diseases such as diabetes and hypertension. Glaucoma treatment is essential for managing chronic eye conditions, as it helps lower intraocular pressure, prevents further damage to the optic nerve, and preserves vision, with untreated glaucoma potentially leading to irreversible blindness. For example, in December 2024, the National Health Service (NHS) reported that over 2 million people in the UK are living with sight loss, a number projected to grow by 27%, reaching approximately 2.8 million by 2035. As a result, the rising prevalence of chronic eye conditions is driving demand in the glaucoma market.

Leading companies in the glaucoma market are focusing on the development of innovative treatments, including Rho-kinase (ROCK) inhibitors, which provide a dual mechanism of action. These therapies reduce intraocular pressure by improving the outflow of aqueous humor and relaxing trabecular meshwork cells, making them highly effective in glaucoma treatment. Rho-kinase (ROCK) inhibitors work by targeting and blocking the Rho-kinase enzymes, which regulate cell contraction and help decrease intraocular pressure. For example, in July 2023, Santen Pharmaceutical Co. Ltd., based in Japan, introduced Roclanda in the UK. Roclanda is a fixed-dose combination (FDC) of latanoprost and netarsudil, a novel Rho-kinase (ROCK) inhibitor, designed to lower intraocular pressure (IOP) by addressing trabecular meshwork dysfunction. It is intended for adult patients with primary open-angle glaucoma or ocular hypertension who have not achieved sufficient IOP reduction with monotherapy involving prostaglandin or netarsudil. The launch of Roclanda in Europe marks the first new class of glaucoma medication in 25 years, representing a significant advancement in treatment. By combining netarsudil and latanoprost, Roclanda enhances outflow through both trabecular (conventional) and uveoscleral (unconventional) pathways, offering a comprehensive solution for managing elevated IOP.

In December 2024, Bausch + Lomb Corp., a Canada-based healthcare company, acquired Elios Vision Inc., a U.S.-based developer of minimally invasive glaucoma surgery (MIGS) procedures. The acquisition is expected to enhance Bausch + Lomb's glaucoma treatment options by providing solutions that do not require implants. This move reflects the company's commitment to advancing technologies that support eye care professionals in addressing patients' evolving needs.

Major players in the glaucoma market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Limited, Bausch & Lomb Corp., Carl Zeiss Meditec, Santen Pharmaceuticals Co. Ltd., Topcon Corporation, Thea Laboratoires, Corza Ophthalmology, Lumenis Ltd., Alcon Inc., Viva BioInnovator, Glaukos Corporation, Iridex Corporation, Nova Eye Medical Ltd., Renova Life Sciences Private Limited, Qlaris Bio Inc., PolyActiva Pty Ltd., Nidek Co. Ltd., Haag-Streit AG.

North America was the largest region in the glaucoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in glaucoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the glaucoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The glaucoma market consists of revenues earned by entities by providing services such as surgical services, telemedicine consultations, treatment monitoring and custom surgical planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The glaucoma market also includes sales of laser treatment devices, glaucoma drainage implants, visual field analyzers and surgical tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Glaucoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on glaucoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for glaucoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The glaucoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Open Angle Glaucoma; Angle Closure Glaucoma; Other Disease Types
• 2) By Diagnosis: Tonometry; Ophthalmoscopy; Perimetry; Gonioscopy
• 3) By Drug Class: Beta Blockers; Prostaglandins; Alpha Adrenergic Agonist; Carbonic Anhydrase Inhibitors; Combination Drugs; Other Drug Classes
• 4) By Administration: Oral; Injections; Intravitreal; Other Administrations
• 5) By End-User: Hospitals; Ophthalmic Clinics; Ambulatory Surgical Centers
• Subsegments:
• 1) By Open Angle Glaucoma: Primary Open Angle Glaucoma (POAG); Secondary Open Angle Glaucoma
• 2) By Angle Closure Glaucoma: Primary Angle Closure Glaucoma; Secondary Angle Closure Glaucoma
• 3) By Other Disease Types: Normal-Tension Glaucoma; Pigmentary Glaucoma; Pseudoexfoliative Glaucoma; Congenital Glaucoma
• Companies Mentioned: Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.; Novartis AG; Teva Pharmaceuticals Industries Ltd.; Otsuka Pharmaceutical Co. Ltd.; Sun Pharmaceutical Industries Ltd.; Cipla Limited; Bausch & Lomb Corp.; Carl Zeiss Meditec; Santen Pharmaceuticals Co. Ltd.; Topcon Corporation; Thea Laboratoires; Corza Ophthalmology; Lumenis Ltd.; Alcon Inc.; Viva BioInnovator; Glaukos Corporation; Iridex Corporation; Nova Eye Medical Ltd.; Renova Life Sciences Private Limited; Qlaris Bio Inc.; PolyActiva Pty Ltd.; Nidek Co. Ltd.; Haag-Streit AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.